Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000234418 | SCV000284139 | pathogenic | Lynch syndrome | 2015-12-14 | criteria provided, single submitter | clinical testing | This sequence change deletes 4 nucleotides from exon 13 of the MSH2 mRNA (c.2150_2153delGTCA), causing a frameshift at codon 717. This creates a premature translational stop signal (p.Ser717Asnfs*2) and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, truncating variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). For these reasons, this variant has been classified as Pathogenic. |
Invitae | RCV001380226 | SCV001578212 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2015-12-14 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. While this particular variant has not been reported in the literature, truncating variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This sequence change deletes 4 nucleotides from exon 13 of the MSH2 mRNA (c.2150_2153delGTCA), causing a frameshift at codon 717. This creates a premature translational stop signal (p.Ser717Asnfs*2) and is expected to result in an absent or disrupted protein product. |